[HTML][HTML] First-generation oral antivirals against SARS-CoV-2
Background Oral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
First-generation oral antivirals against SARS-CoV-2
P Sendi, RR Razonable… - Clinical …, 2022 - mayoclinic.elsevierpure.com
Background: Oral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
[HTML][HTML] First-generation oral antivirals against SARS-CoV-2
P Sendi, RR Razonable, SB Nelson… - Clinical Microbiology …, 2022 - ncbi.nlm.nih.gov
Background Oral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
First-generation oral antivirals against SARS-CoV-2.
P Sendi, RR Razonable, SB Nelson… - … and Infection: the …, 2022 - europepmc.org
Background Oral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
First-generation oral antivirals against SARS-CoV-2
P Sendi, RR Razonable, SB Nelson… - … and infection: the …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Oral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
First-generation oral antivirals against SARS-CoV-2.
P Sendi, RR Razonable, SB Nelson, A Soriano… - 2022 - cabidigitallibrary.org
Background: Oral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
First-generation oral antivirals against SARS-CoV-2
P Sendi, RR Razonable… - Clinical …, 2022 - clinicalmicrobiologyandinfection …
Background Oral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
First-generation Oral Antivirals Against SARS-CoV-2.
P Sendi, RR Razonable, SB Nelson… - Clinical microbiology …, 2022 - boris.unibe.ch
BACKGROUND Oral drugs against SARS-COV-2 have received emergency use
authorization for the treatment of mild-to-moderate COVID-19 in nonhospitalized patients …
authorization for the treatment of mild-to-moderate COVID-19 in nonhospitalized patients …